CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.
Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.
The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.
The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。